An Update on Psychopharmacological Treatment of Autism Spectrum Disorder.
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder.
复制标题
自闭症谱系障碍心理药物治疗的最新信息。
DOI：
10.1007/s13311-022-01183-1
复制
发表时间：
2022-01
影响因子：
5.7
通讯作者：
Restrepo, Bibiana
中科院分区：
文献类型：
--
作者：
Aishworiya, Ramkumar;Valica, Tatiana;Hagerman, Randi;Restrepo, Bibiana
虽然行为干预仍然是自闭症谱系障碍 (ASD) 治疗的支柱，但过去几年出现了几种针对 ASD 潜在神经生理学的潜在靶向治疗方法。这些有望在未来成为解决自闭症谱系障碍核心症状的主要治疗方法的一部分。尽管未来靶向治疗的发展可能会受到病因学潜在异质性的影响，但影响自闭症谱系障碍的相关遗传机制可能是未来自闭症谱系障碍治疗甚至基因治疗的首要目标。在本文中，我们回顾了当前自闭症谱系障碍的精神药理学治疗，包括用于解决常见合并症的治疗方法以及即将推出的自闭症管理新的有针对性的方法。讨论的药物包括二甲双胍、阿巴氯芬、大麻二酚、催产素、布美他尼、洛伐他汀、曲非奈肽，以及膳食补充剂（包括磺基芬和 N-乙酰半胱氨酸）。还回顾了治疗 ASD 相关合并症的常用药物，包括非典型抗精神病药、5-羟色胺能药物、α-2 激动剂和兴奋剂药物。脆性 X 综合征 (FXS) 是导致自闭症谱系障碍 (ASD) 的最常见遗传性疾病，针对它的靶向治疗为新疗法提供了模型，可能有助于其他形式的自闭症谱系障碍 (ASD)。在线版本包含可在 10.1007/s13311-022-01183-1 获取的补充材料。
While behavioral interventions remain the mainstay of treatment of autism spectrum disorder (ASD), several potential targeted treatments addressing the underlying neurophysiology of ASD have emerged in the last few years. These are promising for the potential to, in future, become part of the mainstay treatment in addressing the core symptoms of ASD. Although it is likely that the development of future targeted treatments will be influenced by the underlying heterogeneity in etiology, associated genetic mechanisms influencing ASD are likely to be the first targets of treatments and even gene therapy in the future for ASD. In this article, we provide a review of current psychopharmacological treatment in ASD including those used to address common comorbidities of the condition and upcoming new targeted approaches in autism management. Medications including metformin, arbaclofen, cannabidiol, oxytocin, bumetanide, lovastatin, trofinetide, and dietary supplements including sulforophane and N-acetylcysteine are discussed. Commonly used medications to address the comorbidities associated with ASD including atypical antipsychotics, serotoninergic agents, alpha-2 agonists, and stimulant medications are also reviewed. Targeted treatments in Fragile X syndrome (FXS), the most common genetic disorder leading to ASD, provide a model for new treatments that may be helpful for other forms of ASD. The online version contains supplementary material available at 10.1007/s13311-022-01183-1.
影响因子：
--
作者：
Indah Winarni T;Chonchaiya W;Adams E;Au J;Mu Y;Rivera SM;Nguyen DV;Hagerman RJ
通讯作者：
Hagerman RJ